National Clinician Scholars Program, Philip R. Lee Institute for Health Policy Studies, University of California San Francisco, 290 Illinois Street, Suite 7227, Box 0936, San Francisco, CA, 94158, USA.
San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA.
BMC Emerg Med. 2022 Feb 4;22(1):19. doi: 10.1186/s12873-022-00573-0.
Drug-related emergency department (ED) visits are escalating, especially for stimulant use (i.e., cocaine and psychostimulants such as methamphetamine). We sought to characterize rates, presentation, and management of ED visits related to cocaine and psychostimulant use, compared to opioid use, in the United States (US).
We used 2008-2018 National Hospital Ambulatory Medical Care Survey data to identify a nationally representative sample of ED visits related to cocaine and psychostimulant use, with opioids as the comparator. To make visits mutually exclusive for analysis, we excluded visits related to 2 or more of the three possible drug categories. We estimated annual rate trends using unadjusted Poisson regression; described demographics, presenting concerns, and management; and determined associations between drug-type and presenting concerns (categorized as psychiatric, neurologic, cardiopulmonary, and drug toxicity/withdrawal) using logistic regression, adjusting for age, sex, race/ethnicity, and homelessness.
Cocaine-related ED visits did not significantly increase, while psychostimulant-related ED visits increased from 2008 to 2018 (2.2 visits per 10,000 population to 12.9 visits per 10,000 population; p < 0.001). Cocaine-related ED visits had higher usage of cardiac testing, while psychostimulant-related ED visits had higher usage of chemical restraints than opioid-related ED visits. Cocaine- and psychostimulant-related ED visits had greater odds of presenting with cardiopulmonary concerns (cocaine adjusted odds ratio [aOR] 2.95, 95% CI 1.70-5.13; psychostimulant aOR 2.46, 95% CI 1.42-4.26), while psychostimulant-related visits had greater odds of presenting with psychiatric concerns (aOR 2.69, 95% CI 1.83-3.95) and lower odds of presenting with drug toxicity/withdrawal concerns (aOR 0.47, 95%CI 0.30-0.73) compared to opioid-related ED visits.
Presentations for stimulant-related ED visits differ from opioid-related ED visits: compared to opioids, ED presentations related to cocaine and psychostimulants are less often identified as related to drug toxicity/withdrawal and more often require interventions to address acute cardiopulmonary and psychiatric complications.
与药物相关的急诊就诊(ED)数量不断上升,尤其是与兴奋剂(如可卡因和苯丙胺类兴奋剂)相关的就诊数量。我们旨在描述美国(US)与可卡因和苯丙胺类兴奋剂使用相关的 ED 就诊率、就诊情况和管理方法,并与阿片类药物使用进行比较。
我们使用了 2008 年至 2018 年全国医院门诊医疗调查数据,确定了一个与可卡因和苯丙胺类兴奋剂使用相关的具有全国代表性的 ED 就诊样本,将阿片类药物作为对照。为了使就诊情况在分析中相互排斥,我们排除了与三种可能药物类别中的两种或更多类别相关的就诊情况。我们使用未调整的泊松回归估计年度率趋势;描述人口统计学、就诊关注点和管理方法;并使用逻辑回归确定药物类型与就诊关注点(分为精神病、神经病、心肺和药物毒性/戒断)之间的关联,同时调整年龄、性别、种族/民族和无家可归状况。
可卡因相关的 ED 就诊数量没有明显增加,而苯丙胺类兴奋剂相关的 ED 就诊数量从 2008 年到 2018 年有所增加(每 10000 人中有 2.2 次就诊增加到每 10000 人中有 12.9 次就诊;p<0.001)。可卡因相关的 ED 就诊情况中,心脏检测的使用率较高,而苯丙胺类兴奋剂相关的 ED 就诊情况中,化学约束的使用率高于阿片类药物相关的 ED 就诊情况。可卡因和苯丙胺类兴奋剂相关的 ED 就诊情况中,出现心肺问题的可能性更大(可卡因调整后的比值比[aOR]为 2.95,95%置信区间[CI]为 1.70-5.13;苯丙胺 aOR 为 2.46,95%CI 为 1.42-4.26),而苯丙胺类兴奋剂相关的就诊情况中,出现精神科问题的可能性更大(aOR 为 2.69,95%CI 为 1.83-3.95),出现药物毒性/戒断问题的可能性更小(aOR 为 0.47,95%CI 为 0.30-0.73),与阿片类药物相关的 ED 就诊情况相比。
与兴奋剂相关的 ED 就诊情况与阿片类药物相关的就诊情况不同:与阿片类药物相比,与可卡因和苯丙胺类兴奋剂相关的 ED 就诊情况较少被确定与药物毒性/戒断有关,而更多地需要进行干预以解决急性心肺和精神科并发症。